Massachusetts lawmakers have approved a bill to establish a pilot program for the regulated therapeutic use of psychedelics, which has advanced through the legislature's Joint Committee on Health Care Financing. The bill, S.1400, proposes a monitored mental health care program using psychedelic materials, administered on-site by a multi-disciplinary care team in supervised licensed mental health clinics. The Department of Public Health (DPH) would license up to three facilities to administer and study psychedelics, focusing on establishing best clinical practices and collecting patient outcome data for depression, anxiety, PTSD, and substance use disorder. The bill specifies that eligible organizations must focus exclusively on mental health and cannot be affiliated with cannabis, psychedelic molecule development, or pharmaceutical companies. A separate, more limited psilocybin therapy bill will also be heard in November. This legislative effort follows local decriminalization initiatives and a rejected statewide ballot measure to legalize psychedelics. The state has also been active in cannabis policy, with discussions on consumption lounges, employment protections for consumers, and expanding medical cannabis qualifying conditions.

Massachusetts Approves Psychedelic Therapy Pilot Program

Sep 12, 2025

Source:

Kyle Jaeger

Marijuana Moment

Massachusetts lawmakers are making moves to explore the therapeutic potential of psychedelics, recently advancing a bill to create a regulated pilot program. This proposal, which just cleared a key joint committee, aims to license up to three mental health facilities to study and administer these substances in a supervised clinical environment. The focus is strictly on treating conditions like depression, anxiety, and PTSD, with a clear line drawn to keep big pharma and the cannabis industry separate from these specific pilot organizations.

While voters previously turned down a broader legalization measure, this legislative shift shows that the state is still serious about alternative medicine. For the cannabis community, this is a major win because it signals a growing acceptance of plant-based and entheogenic therapies. As the lines between different natural medicines continue to blur, progress in the psychedelic space often paves the way for more progressive cannabis policies. It’s all about expanding our toolkit for wellness and proving that regulated, therapeutic access works.

Recent Reviews

Mountain High Black Cherry: Elevating the Low-Dose Category

Mountain High is expanding its lineup with Black Cherry, a new release that continues the brand’s tradition of thoughtful flavor, balanced effects, and an easygoing drinking experience suitable for almost any occasion. Available through the brand’s new website and at hundreds of retailers across Virginia, Black Cherry arrives with high expectations — and meets them gracefully...

Fade Co.'s Live Concentrates Lineup at Story Mechanicsville: A Connoisseur’s Tour

Fade Co. continues to demonstrate why it remains one of Maryland’s most consistent and interesting concentrate producers. Currently in stock at Story Dispensary in Mechanicsville, their latest live sugar and live badder lineup offers a diverse range of profiles — from bold, gassy hybrids to bright, fruit-forward sativas and soothing indicas.

Koosh The Magic Dragon | Byline | Virginia Homegrown

Koosh The Magic Dragon (KTMD) feels like the cannabis world’s best-kept secret — a strain that hasn’t yet gone mainstream but already has that quiet “you had to be there” reputation. Bred by Byline, this relatively new genetic is still circulating mostly through craft grower networks rather than dominating every dispensary shelf. That limited exposure gives it a charming underground mystique, like a dragon that only reveals itself to those worthy of its smoke...

2 3 4 5

Menu